Reliance, Faradion, and the Jamnagar Gamble: India's Play to Break China's Next Battery Monopoly

The coordinates are familiar. Jamnagar, on Gujarat's Arabian Sea coast, is home to the world's largest single-location oil refinery, where Reliance Industries processes 1.4 million barrels of crude every day. For three decades, this complex has symbolized India's dependence on imported fossil fuels. Now, within the same industrial perimeter, Reliance is building something that could rewrite that story: a battery gigafactory with an initial capacity target of 40 gigawatt-hours, where sodium-ion technology will sit alongside lithium-ion production.

The logic is not coincidence. It is strategy.

The Sheffield Acquisition

In January 2022, Reliance New Energy Ltd completed its acquisition of Faradion Limited, a sodium-ion battery startup based in Sheffield, England, for approximately $135 million. Faradion had been founded in 2011 in Sheffield, with its chief scientist later appointed honorary professor at the University of St Andrews. It was not a garage experiment. The company held one of the most advanced non-Chinese patent portfolios in sodium-ion electrochemistry, with intellectual property covering layered oxide cathode materials, cell design, and manufacturing processes.

Faradion had demonstrated a 32 ampere-hour pouch cell achieving 160 Wh/kg at the cell level. It had put sodium-ion batteries into an e-bike in 2015 and an e-scooter shortly after, the first company to do so publicly. Its cathode chemistry avoids cobalt entirely, using a layered transition metal oxide with sodium that sidesteps one of lithium-ion's most geopolitically fraught supply chain bottlenecks.

At the time of acquisition, CATL had announced its intention to produce sodium-ion batteries but had not yet shipped a commercial cell. Reliance moved before the Chinese mass-production wave materialized. Whether that timing was prescient or fortunate matters less than what it produced: India now holds non-Chinese sodium-ion IP with a credible path to manufacturing.

The Pharma Playbook

India has broken a monopoly before. The parallel is not rhetorical. It is structural.

In 1970, India's parliament passed a new Patents Act that abolished product patents for pharmaceuticals, allowing Indian companies to develop alternative manufacturing processes for existing drugs. Over the following three decades, companies like Cipla, Dr. Reddy's, and Sun Pharma built a generic pharmaceutical industry that made India the world's largest supplier of generic medicines by volume, accounting for roughly 20 percent of global output and close to half of all generic prescriptions filled in the United States. The landmark moment came in 2001, when Cipla offered antiretroviral AIDS treatment at $350 per patient per year, against the prevailing price of over $10,000. That single act reshaped global health access and demonstrated the power of Indian industrial capacity deployed against an entrenched monopoly.

India re-introduced product patents in 2005 under WTO TRIPS obligations, but with a critical safeguard: Section 3(d), which restricts patents on minor modifications of known substances. The section has been upheld by Indian courts, most notably in the 2013 Novartis case involving Glivec, and continues to prevent pharmaceutical evergreening. The result was an ecosystem where legal clarity enabled industrial confidence, and industrial confidence enabled scale.

The battery parallel runs along the same structural lines. Acquire intellectual property. Build domestic manufacturing capacity at a cost base lower than incumbents. Scale for export. In pharmaceuticals, Hyderabad and Mumbai became global production hubs because Indian companies combined Western formulation science with Indian manufacturing economics. In batteries, the question is whether Jamnagar can replicate that synthesis: Faradion's Sheffield electrochemistry scaled through Indian industrial capacity.

The differences are real and should not be smoothed over. Pharmaceutical patents expired on a predictable schedule, giving Indian generics makers a clear timeline for market entry. Battery chemistry IP is newer, more actively contested, and the incumbent, China, is not a patent holder defending margins but a manufacturing colossus defending cost advantages. The speed requirement is different too. India's pharma revolution took two decades to reach global significance. The sodium-ion window may be five years before Chinese scale economics close it.

Jamnagar: One Complex, Two Energy Eras

The choice of Jamnagar for sodium-ion production is less about symbolism than about infrastructure. The refinery complex already has power supply sufficient for industrial-scale manufacturing, established chemical handling and logistics, deepwater port access for both import and export, a trained industrial workforce, and the surrounding chemical ecosystem of Gujarat.

Gujarat is not merely a convenient location. It is the center of India's soda ash industry. The state accounts for roughly 90 percent of Indian soda ash production, with major operations run by Tata Chemicals at Mithapur, GHCL at Sutrapada, and Nirma's chemical division. India produced approximately 3.8 million tonnes of soda ash in 2024, making it one of the world's leading producers, though still well behind China, the United States, and Turkey.

This matters because sodium-ion batteries need sodium carbonate as a primary feedstock. Unlike lithium, where India imports nearly 100 percent of its requirements and depends on Australian mining and Chinese processing to reach battery-grade material, sodium-ion's core chemistry aligns with an industry that already exists in India, within trucking distance of Jamnagar.

Hard carbon, the anode material replacing graphite in sodium-ion cells, offers another alignment. It can be produced from biomass precursors, including coconut shells and agricultural waste. India generates roughly 500 million tonnes of crop residue annually, much of it burned in open fields. Converting a fraction into hard carbon for battery anodes would be industrially modest but symbolically powerful.

Reliance's bet is on vertical integration: chemical precursors, cell manufacturing, and module assembly in one ecosystem. The approach mirrors what CATL built in Ningde over a decade. The question is whether it can be compressed into a fraction of that time.

CATL's Shadow Over Jamnagar

China is not waiting for India to catch up. In February 2026, CATL and Changan unveiled the Nevo A06, the first mass-produced passenger car equipped with sodium-ion batteries, targeted for market launch by mid-2026. CATL's first-generation sodium-ion cells claim 160 Wh/kg energy density, broadly comparable to Faradion's demonstrated figures.

HiNa Battery, backed by the Chinese Academy of Sciences' Institute of Physics, already has operational sodium-ion pilot production. BYD, though publicly focused on its Blade Battery lithium iron phosphate technology, is developing sodium-ion variants and has commissioned a 30 GWh sodium-ion line. Across China, sodium-ion production capacity under construction or planned exceeds 100 GWh, spread among CATL, HiNa, BYD, Hithium, and a growing roster of smaller producers.

The competitive landscape is not India against the world. It is India against Chinese mass production timelines. Chinese battery manufacturers have spent fifteen years perfecting lithium-ion production at a scale no other country has matched. They will bring the same manufacturing discipline to sodium-ion. If Reliance cannot reach cost parity within a three-to-five-year window, Jamnagar risks becoming a monument to ambition rather than achievement.

The scale disparity is stark. Reliance's gigafactory, even at its full 40 GWh target, would represent a fraction of China's sodium-ion buildout. In lithium-ion, CATL alone sold over 660 GWh in 2025. China's battery manufacturers have driven lithium iron phosphate pack prices to approximately $81 per kilowatt-hour, a level that European and American factories cannot yet match even with billions in subsidies. Sodium-ion promises to go lower still, with industry projections suggesting cell costs could reach $40 per kilowatt-hour at scale. If Chinese producers reach that floor first, the cost advantage becomes a moat that no competitor, Indian or otherwise, can easily cross.

The question for Jamnagar is not whether it can make sodium-ion cells. It is whether it can make them cheaply enough, fast enough, to establish a position before Chinese exports flood every market India cares about. India has one structural defense: import tariffs. India maintains customs duties on lithium-ion cells and higher rates on finished battery packs. Whether the government extends similar protection to sodium-ion, and whether protection alone can buy enough time for domestic scale, remains an open question.

The PLI Lever

India's Production Linked Incentive scheme for Advanced Chemistry Cells, approved in 2021, allocates INR 18,100 crore (approximately $2.2 billion) in subsidies for domestic battery manufacturing. The subsidy, capped at 20 percent of cell sales price, represents a significant offset in an industry where every dollar per kilowatt-hour of cost reduction matters.

The PLI scheme's design may prove fortunate for sodium-ion. Its language refers to "advanced chemistry cells" without specifying lithium-ion or any particular electrochemistry. Reliance is among the PLI beneficiaries, having secured 5 GWh in the initial allocation and an additional 10 GWh in a 2025 retender, alongside Ola Electric and Rajesh Exports. NITI Aayog's 2022 battery swapping policy also avoids mandating a specific chemistry.

In principle, sodium-ion qualifies. In practice, the implementation guidelines, testing protocols, and capacity verification processes have been built around lithium-ion assumptions. Whether the bureaucratic machinery of India's Ministry of Heavy Industries adjusts its interpretation to explicitly include sodium-ion, and how fast, could determine the financial viability of Reliance's Jamnagar line.

This is a familiar Indian pattern: the policy architecture exists, the legal language permits, but the administrative execution lags. The PLI scheme is a lever that could accelerate Jamnagar by years. It could also remain effectively lithium-only through institutional inertia.

The OEM Question

A battery factory without customers is an expensive warehouse. Reliance needs Indian vehicle manufacturers to commit to sodium-ion platforms, and so far, no major Indian automaker has done so publicly.

Mahindra sources lithium-ion cells from BYD and Farasis for its EV lineup. Tata Motors, through the Tata Group's Agratas subsidiary, is building a 20 GWh lithium-ion gigafactory in Gujarat. Ola Electric received PLI approval for lithium-ion cell manufacturing. The entire Indian EV supply chain is, as of early 2026, organized around lithium.

But the Indian EV market has a structural characteristic that distinguishes it from Western markets: two-wheelers and three-wheelers dominate sales. India sold over 20 million two-wheelers in 2025, and the electric two-wheeler segment is growing faster than any other EV category. For scooters, rickshaws, and urban micro-vehicles, sodium-ion's lower energy density is a non-issue. What matters is cost per cycle, tolerance for temperature extremes, and safety. On all three metrics, sodium-ion competes with or exceeds lithium iron phosphate.

The chicken-and-egg problem, cell supply waiting for OEM demand and vice versa, is real. But the market structure favors sodium-ion more than most analysts outside India recognize. If Reliance can offer sodium-ion cells at $30-40 per kilowatt-hour at scale, the two-wheeler and three-wheeler segment has the volume to absorb production and the price sensitivity to reward it.

Breaking the Monopoly Before It Forms

The strategic logic of India's sodium-ion play is historically unusual. Most monopoly-breaking happens after the fact. India's pharmaceutical revolution dismantled Western pharma's grip after decades of consolidated market power. Japan's semiconductor challenge to American dominance in the 1980s came after Intel and Texas Instruments had defined the industry.

Sodium-ion is different. China dominates lithium-ion battery manufacturing, controlling approximately 80 percent of global cell production and processing 60 to 70 percent of global lithium into battery-grade chemicals. But sodium-ion is still in its commercial infancy. The monopoly has not yet consolidated. The supply chains are not yet locked in. The window for a challenger is open.

India has the raw materials. Gujarat's soda ash industry and agricultural biomass give it a domestic precursor base that no other non-Chinese sodium-ion aspirant possesses. India has the policy framework. The PLI scheme, FAME incentives, and NITI Aayog's battery roadmap provide a subsidy architecture, even if the bureaucratic details lag. India has the corporate champion. Reliance's total new energy investment commitment exceeds $10 billion, encompassing solar, green hydrogen, and batteries. And India has the market structure. A two-wheeler-dominated EV market is tailor-made for sodium-ion's cost and durability profile.

What India does not have is production at scale. Faradion's IP is proven in the laboratory and in prototypes. Jamnagar's gigafactory does not yet exist in full operation. The jump from demonstrated cell to mass-manufactured product at competitive cost is where most battery ventures fail.

In Hyderabad, India built a pharmaceutical capital that changed global health access. The question is whether Jamnagar can become the equivalent for energy storage. The pharma playbook took twenty years. The sodium-ion window may close in five. The raw materials, the policy, and the strategy are aligned. What remains is the hardest part: building the factory and making it work before the Chinese alternatives make it irrelevant.